Next Article in Journal
Special Issue on “Mapping and Monitoring of Geohazards”
Next Article in Special Issue
Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib
Previous Article in Journal
Using Ensembles for Accurate Modelling of Manufacturing Processes in an IoT Data-Acquisition Solution
Review

Treatment Selection for Early to Intermediate Hepatocellular Carcinoma

1
Department of Gastroenterology, Okayama City Hospital, Okayama 700-8558, Japan
2
Mitsui Memorial Hospital, Tokyo 101-8643, Japan
3
Kanazawa University, Kanazawa 920-1192, Japan
4
Hyogo College of Medicine, Hyogo 663-8501, Japan
5
Taipei Veterans General Hospital, Taipei 11217, Taiwan
6
Samsun Medical Center, Seoul 06351, Korea
7
Seoul National University Hospital, Seoul 03080, Korea
8
Asan Medical Center, Seoul 05505, Korea
9
TATA Memorial Hospital, Mumbai 400 012, India
10
Rela Institute and Medical Center, Chennai 600 044, India
11
Yokokura Hospital, Fukuoka 839-0295, Japan
*
Author to whom correspondence should be addressed.
Appl. Sci. 2020, 10(13), 4607; https://doi.org/10.3390/app10134607
Received: 29 May 2020 / Revised: 28 June 2020 / Accepted: 29 June 2020 / Published: 3 July 2020
(This article belongs to the Special Issue Treatment Strategies for Hepatocellular Carcinoma)
Many guidelines and standard therapies have been published for the treatment of hepatocellular carcinoma (HCC). Multiple options for the treatment of early to intermediate-stage HCC have resulted in several differences between the guidelines. In addition, more than a few non-standard therapies have been used in a real-world clinical setting. Radiofrequency ablation or chemotherapy, including hepatic arterial infusion chemotherapy and molecular target agents, are sometimes selected for the treatment of intermediate HCC, whereas in many guidelines, the recommended therapy for these patients is transcatheter arterial chemoembolization. The present status of these topics is reviewed and summarized. View Full-Text
Keywords: hepatocellular carcinoma; treatments; radiofrequency ablation; molecular target agents; hepatic arterial infusion chemotherapy hepatocellular carcinoma; treatments; radiofrequency ablation; molecular target agents; hepatic arterial infusion chemotherapy
Show Figures

Figure 1

MDPI and ACS Style

Nouso, K.; Ohki, T.; Yamashita, T.; Takaki, H.; Liu, C.-A.; Kang, T.W.; Lee, D.H.; Lee, S.J.; Kulkarni, S.; Shree, D.; Tanaka, M. Treatment Selection for Early to Intermediate Hepatocellular Carcinoma. Appl. Sci. 2020, 10, 4607. https://doi.org/10.3390/app10134607

AMA Style

Nouso K, Ohki T, Yamashita T, Takaki H, Liu C-A, Kang TW, Lee DH, Lee SJ, Kulkarni S, Shree D, Tanaka M. Treatment Selection for Early to Intermediate Hepatocellular Carcinoma. Applied Sciences. 2020; 10(13):4607. https://doi.org/10.3390/app10134607

Chicago/Turabian Style

Nouso, Kazuhiro; Ohki, Takamasa; Yamashita, Tatsuya; Takaki, Haruyuki; Liu, Chien-Au; Kang, Tae W.; Lee, Dong H.; Lee, So J.; Kulkarni, Suyash; Shree, Deepa; Tanaka, Masatoshi. 2020. "Treatment Selection for Early to Intermediate Hepatocellular Carcinoma" Appl. Sci. 10, no. 13: 4607. https://doi.org/10.3390/app10134607

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop